Csenge Advisory Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Csenge Advisory Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3	Closed	–	–	359
2018 Q3	$0	Buy	+3	New	+$299	﹤0.01%	1088

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Csenge Advisory Group's BMRN Position: Q4 2018 in Review

Csenge Advisory Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 3 shares.

Csenge Advisory Group first reported a position in BMRN in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 472 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

Csenge Advisory Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Csenge Advisory Group sold 3 BioMarin Pharmaceuticals shares in Q4 2018.
Csenge Advisory Group first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Csenge Advisory Group's BioMarin Pharmaceuticals position peaked at $0 in Q3 2018.
472 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.